M.D. Anderson to Hold Conference in Spanish

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 4
Volume 5
Issue 4

HOUSTON--The University of Texas M.D. Anderson Cancer Center will hold its second medical oncology conference in Spanish on May 22-24, 1996. The educational conference will bring together physicians from Spain and Latin American with the M.D. Anderson faculty, said Richard Pazdur, MD, associate professor of medicine and co-director of the conference along with Alejandro Preti, MD, assistant professor of medicine.

HOUSTON--The University of Texas M.D. Anderson Cancer Center willhold its second medical oncology conference in Spanish on May22-24, 1996. The educational conference will bring together physiciansfrom Spain and Latin American with the M.D. Anderson faculty,said Richard Pazdur, MD, associate professor of medicine and co-directorof the conference along with Alejandro Preti, MD, assistant professorof medicine.

"I think M.D. Anderson is unique in that it has such a diversegroup of Spanish-speaking faculty, both native speakers and thosewho learned the language along the way," Dr. Pazdur saidin an interview. Most of the speakers are M.D. Anderson faculty.In addition, physicians from Spain have been invited to discusstheir research work at a symposium to be held in conjunction withthe conference.

ASCO Findings Will Be Reviewed

The meeting will also provide an opportunity for a discussionof studies presented at the 1996 American Society of ClinicalOncology (ASCO) meeting, to put new findings into the contextof existing therapies, Dr. Pazdur said. He expects between 50and 100 physicians to attend the conference.

Recent Videos
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
2 experts are featured in this series.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
A collaboration between the Connecticut Departments of Health and Corrections and the COPPER Center aimed to improve outcomes among incarcerated patients.
Related Content